Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This will be a dose escalation study to determine the maximum tolerated dose (MTD) and the
overall safety and tolerability of a topical compound 31543 (Calcitriol) in patients with
metastatic or recurrent cancer who are undergoing chemotherapy with a taxane-based regimen.